Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deupirfenidone - PureTech Health

Next Previous
Drug Profile

Deupirfenidone - PureTech Health

Alternative Names: Deuterated pirfenidone; Deuterium-substituted pirfenidone; LYT-100; LYT-100-COV; LYT-100-ILD; LYT-100-LYMPH; Pirfenidone deuterated; SD-560

Latest Information Update: 22 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer PureTech Health
  • Class Anti-infectives; Anti-inflammatories; Antifibrotics; Organic deuterium compounds; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Lymphoedema
  • Discontinued Post acute COVID 19 syndrome

Most Recent Events

  • 20 Dec 2023 PureTech Health plans a phase-III trial for Idiopathic pulmonary fibrosis in USA
  • 11 Oct 2023 Pharmacokinetics and adverse events data from a phase I trial in Idiopathic pulmonary fibrosis released by PureTech
  • 11 Oct 2023 PureTech completes a phase I trial in idiopathic pulmonary fibrosis in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top